Scarica l'app Stockscreener
1.60
3.03%
-0.05
Dopo l'orario di chiusura:
1.55
-0.05
-3.13%
Precedente Chiudi:
$1.65
Aprire:
$1.43
Volume 24 ore:
6.70M
Relative Volume:
28.60
Capitalizzazione di mercato:
$7.32M
Reddito:
$895.50K
Utile/perdita netta:
$-26.30M
Rapporto P/E:
-0.9756
EPS:
-1.64
Flusso di cassa netto:
$-23.84M
1 W Prestazione:
+2.56%
1M Prestazione:
-2.44%
6M Prestazione:
-47.71%
1 anno Prestazione:
-86.21%
Intervallo 1D:
$1.2801
$1.66
Intervallo di 1 settimana:
$1.2801
$1.75
Portata 52W:
$1.2801
$16.04
Mainz Biomed N V Stock (MYNZ) Company Profile
Nome
Mainz Biomed N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MYNZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
1.60 | 7.55M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
536.19 | 203.60B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
204.96 | 149.49B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
629.91 | 50.19B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
140.81 | 39.28B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
200.60 | 34.15B | 15.70B | 1.24B | 2.01B | 6.9036 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | Maxim Group | Buy |
| 2024-11-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | Iniziato | H.C. Wainwright | Buy |
Mainz Biomed N V Borsa (MYNZ) Ultime notizie
Mainz Biomed reports promising results for pancreatic cancer blood test By Investing.com - Investing.com Nigeria
Mainz Biomed reports promising results for pancreatic cancer blood test - Investing.com India
Mainz Biomed N.V. Reports Positive Results from Feasibility Study for Non-Invasive Pancreatic Cancer Screening Test - Quiver Quantitative
100% sensitivity: Mainz Biomed biomarker panel shows 95% specificity in 30‑patient pancreatic study - Stock Titan
What analysts say about Mainz Biomed NV stockMarket Correction Analysis & Outstanding Profit Strategies - earlytimes.in
Can Mainz Biomed N.V. recover in the next quarter2025 Analyst Calls & Verified Entry Point Detection - newser.com
Visual analytics tools that track Mainz Biomed N.V. performanceInsider Selling & AI Forecasted Stock Moves - newser.com
What MACD and RSI say about Mainz Biomed N.V.CPI Data & High Return Stock Watch Alerts - newser.com
How forex fluctuations impact Mainz Biomed N.V. (4TO) stockWeekly Volume Report & Technical Analysis for Trade Confirmation - newser.com
How Mainz Biomed N.V. (4TO) stock expands through international marketsTake Profit & Verified Momentum Stock Ideas - newser.com
Will Mainz Biomed N.V. (4TO) stock benefit from mergersWeekly Gains Report & Low Risk Entry Point Tips - newser.com
Real time breakdown of Mainz Biomed N.V. stock performance2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
Real time pattern detection on Mainz Biomed N.V. stockSell Signal & Daily Growth Stock Tips - newser.com
Can swing trading help recover from Mainz Biomed N.V. lossesJuly 2025 Momentum & Weekly Breakout Stock Alerts - newser.com
How Mainz Biomed N.V. (4TO) stock reacts to monetary easingTrade Volume Summary & Weekly High Momentum Picks - newser.com
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting - GlobeNewswire
97% Accuracy: Mainz Biomed's Revolutionary RNA Test Could Transform Early Colorectal Cancer Detection - Stock Titan
Published on: 2025-09-30 00:50:22 - newser.com
Can Mainz Biomed N.V. (4TO) stock double in coming yearsQuarterly Trade Report & Weekly Momentum Picks - newser.com
Mainz Biomed N V Azioni (MYNZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.92%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):